Skip to contentpdufa.bio

Relutrigine EMERALD

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

Relutrigine EMERALD is a Praxis Precision Medicines Inc. program in broad developmental and epileptic encephalopathies (DEEs). Its next catalyst is a Readout in Q4 2026.

PRAX catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: Broad developmental and epileptic encephalopathies (DEEs). Sponsor: Praxis Precision Medicines Inc. (PRAX). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q4 2026PRAX

Specialist biotech funds holding PRAX, 13F for the quarter ended September 30, 2026

FundSharesValue at quarter endFiling
Perceptive Advisors2,024,781$589.7 millionfiled November 16, 2026
Baker Bros. Advisors1,753,198$510.6 millionfiled November 16, 2026
Cormorant Asset Management500,000$145.6 millionfiled November 16, 2026
OrbiMed Advisors200,400$58.4 millionfiled November 16, 2026

13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.

Questions

When is Relutrigine EMERALD's next FDA decision or readout?

The next tracked catalyst for Relutrigine EMERALD is a Readout in Q4 2026.

What happened at Relutrigine EMERALD's most recent FDA decision?

No FDA decision for Relutrigine EMERALD is in our archive yet.

What is Relutrigine EMERALD used for?

In our records Relutrigine EMERALD is under review or in development for Broad developmental and epileptic encephalopathies (DEEs).

Who makes Relutrigine EMERALD?

Praxis Precision Medicines Inc. (PRAX).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.